Skip to NavigationSkip to content

Ondexxya

Alexion's Ondexxya approved for NHS Scotland to treat uncontrolled and life-threatening bleeds

The Scottish Medicines Consortium (SMC) has given its recommendation to Alexion’s Ondexxya (andexanet alfa) to routine use on NHS Scotland for the treatment of life-threatening or uncontrolled bleeding in adult patients treated with the direct Factor Xa (FXa) inhibitors apixaban or rivaroxaban, it has emerged.

According to data harvested from two Phase 3 studies and a Phase 3b safety study, Ondexxya was shown to “markedly reduce” anti-factor Xa activity of apixaban and rivaroxaban, while 82% of evaluable patients receiving the drug saw their bleeding stop 12 hours after treatment c

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches